Vertex Pharmaceuticals VRTX Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations.
The official record: Vertex Pharmaceuticals’s 10-K, filed February 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vertex Pharmaceuticals's unrecognized tax benefits reductions resulting from lapse of applicable statute of limitations.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vertex Pharmaceuticals's unrecognized tax benefits reductions resulting from lapse of applicable statute of limitations?
- Vertex Pharmaceuticals (VRTX) reported unrecognized tax benefits reductions resulting from lapse of applicable statute of limitations of $2.68M in Q4 2025.
- How has Vertex Pharmaceuticals's unrecognized tax benefits reductions resulting from lapse of applicable statute of limitations changed year-over-year?
- Vertex Pharmaceuticals's unrecognized tax benefits reductions resulting from lapse of applicable statute of limitations decreased by 35.5% year-over-year, from $4.15M to $2.68M.
- What is the long-term trend for Vertex Pharmaceuticals's unrecognized tax benefits reductions resulting from lapse of applicable statute of limitations?
- Over 2 years (2023 to 2025), Vertex Pharmaceuticals's unrecognized tax benefits reductions resulting from lapse of applicable statute of limitations has grown at a 14.9% compound annual growth rate (CAGR), from $8.1M to $10.7M.